Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the real world clinical effectiveness of olaparib maintenance monotherapy by investigator assessed progression free survival (PFS) according to modified Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 in patients with sBRCAm ovarian cancer. To assess the real world clinical effectiveness of olaparib maintenance monotherapy by investigator assessed PFS according to RECIST 1.1 in patients with BRCAm ovarian cancer.
Critère d'inclusion
- BRCA or HRR+ Mutated Ovarian Cancer Patients